BIIB
Biogen Inc (BIIB) Sec Form 8K
Biogen Inc (NASDAQ: BIIB) Sec Form 8K
Biogen Inc (BIIB) Sec Form 8K
Biogen Inc (NASDAQ: BIIB) Sec Form 8K
Biogen Inc (BIIB) FDA Approves New High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy
Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release
Biogen Inc (BIIB) Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release
Biogen Inc (BIIB) Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release
Biogen Inc (BIIB) Sec Form 8K
Biogen Inc (NASDAQ: BIIB) Sec Form 8K
Biogen Inc (BIIB) Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release
Biogen Inc (BIIB) The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release
Biogen Inc (BIIB) Sec Form 8K
Biogen Inc (NASDAQ: BIIB) Sec Form 8K
Biogen Inc (BIIB) Biogen Announces Board Chair Transition
Biogen Inc (NASDAQ: BIIB) FY 2026 Management Update